Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.
Mina Hassan-ZahraeeZhan YeLi XiMary Lynn BanieckiXingpeng LiCraig L HydeJenny ZhangNancy RahaFridrik KarlssonJie QuanDaniel ZiemekSrividya NeelakantanChristopher LepsyJessica R AllegrettiJacek RomatowskiEllen J ScherlMaria KlopockaSilvio DaneseDeepa E ChandraUwe SchoenbeckMichael S VincentRandy LongmanKenneth E HungPublished in: Inflammatory bowel diseases (2021)
The ability of PF-06480605 to engage and inhibit colonic TL1A, targeting inflammatory T cell and fibrosis pathways, provides the first-in-human mechanistic data to guide anti-TL1A therapy for the treatment of IBD.